Jackson Grant Investment Advisers Inc. Raises Holdings in Bristol-Myers Squibb (NYSE:BMY)

Jackson Grant Investment Advisers Inc. increased its position in Bristol-Myers Squibb (NYSE:BMY) by 6.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 6,513 shares of the biopharmaceutical company’s stock after purchasing an additional 416 shares during the period. Jackson Grant Investment Advisers Inc.’s holdings in Bristol-Myers Squibb were worth $368,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Confluence Wealth Services Inc. boosted its stake in Bristol-Myers Squibb by 22.0% during the 4th quarter. Confluence Wealth Services Inc. now owns 12,748 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 2,302 shares during the period. Lion Street Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 6.1% in the fourth quarter. Lion Street Advisors LLC now owns 12,635 shares of the biopharmaceutical company’s stock valued at $715,000 after buying an additional 727 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Bristol-Myers Squibb by 12.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,566,160 shares of the biopharmaceutical company’s stock worth $89,051,000 after buying an additional 172,439 shares during the period. Sargent Investment Group LLC increased its position in Bristol-Myers Squibb by 90.5% in the 4th quarter. Sargent Investment Group LLC now owns 17,656 shares of the biopharmaceutical company’s stock valued at $977,000 after acquiring an additional 8,387 shares during the period. Finally, Old North State Wealth Management LLC raised its stake in Bristol-Myers Squibb by 13.2% during the 4th quarter. Old North State Wealth Management LLC now owns 9,283 shares of the biopharmaceutical company’s stock valued at $526,000 after acquiring an additional 1,079 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on BMY. Cantor Fitzgerald boosted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Morgan Stanley raised their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective on the stock. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $56.93.

Bristol-Myers Squibb Stock Up 0.9 %

Bristol-Myers Squibb stock opened at $59.66 on Thursday. The firm has a market capitalization of $121.01 billion, a price-to-earnings ratio of -16.62, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The stock’s fifty day moving average is $57.64 and its two-hundred day moving average is $53.59.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.16%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is presently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.